^
    Back
    Association details:
    Biomarker:ALK positive
    Cancer:Lung Adenocarcinoma
    Drug:Lorbrena (lorlatinib) (ALK inhibitor, ROS1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C1 - Off-label
      (Approved for Non Small Cell Lung Cancer)
    New
    Title:

    European Commission Approves LORVIQUA® (lorlatinib) as a First-Line Treatment for ALK-Positive Advanced Lung Cancer

    Excerpt:
    Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) granted marketing authorization for LORVIQUA® (lorlatinib, available in the U.S. under the brand name LORBRENA®) as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)- positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Thorac Cancer
    Title:

    Successful treatment of refractory brain metastases from ALK-positive lung cancer with lorlatinib

    Published date:
    04/04/2022
    Excerpt:
    A 44-year-old woman with ALK-positive advanced adenocarcinoma of the lung...we switched to lorlatinib, and found a reduction in brain metastases.
    DOI:
    10.1111/1759-7714.14406
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Medicine (Baltimore)
    Title:

    Successful treatment with lorlatinib in a patient with meningeal carcinomatosis of ALK-positive non-small cell lung cancer resistant to alectinib and brigatinib: A case report

    Published date:
    10/01/2021
    Excerpt:
    Here, we report a case of ALK-positive lung adenocarcinoma with meningeal carcinomatosis in which lorlatinib was used after resistance to alectinib and brigatinib….At 8 months from the initiation of lorlatinib, the patient remained well without disease progression.
    DOI:
    10.1097/MD.0000000000027385